Trial Profile
A Randomised, Double-Blind, Placebo-Controlled Study of a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) of a FimH Antagonist, EB8018, in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2018
Price :
$35
*
At a glance
- Drugs Sibofimloc (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Sponsors Enterome
- 01 Jun 2018 According to an Enterome media release, data will be presented at the Digestive Disease Week 2018.
- 27 Oct 2017 According to an Enterome media release, results from this trial will be presented at an upcoming medical congress.
- 27 Oct 2017 Status changed from recruiting to completed according to an Enterome media release.